Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2

•TB and COVID-19 coinfection does not affect M. tuberculosis-specific response.•TB and COVID-19 coinfection limits the ability to in vitro respond to SARS-CoV-2.•Latent TB infection does not affect the ability to in vitro respond to SARS-CoV-2. The interaction of COVID-19 and tuberculosis (TB) are s...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:International journal of infectious diseases Ročník 113; s. S82 - S87
Hlavní autori: Petrone, Linda, Petruccioli, Elisa, Vanini, Valentina, Cuzzi, Gilda, Gualano, Gina, Vittozzi, Pietro, Nicastri, Emanuele, Maffongelli, Gaetano, Grifoni, Alba, Sette, Alessandro, Ippolito, Giuseppe, Migliori, Giovanni Battista, Palmieri, Fabrizio, Goletti, Delia
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Canada Elsevier Ltd 01.12.2021
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases
Elsevier
Predmet:
Antigens, Bacterial - immunology
Antigens, Viral - immunology
Co-infection
Coinfection
COVID-19
COVID-19 - immunology
Humans
IFN-gamma response
Interferon-gamma - immunology
M. tuberculosis
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Tuberculosis
Tuberculosis - immunology
Whole blood assay
COVID-19
Tuberculosis
Co-infection
IFN-gamma response
M. tuberculosis
Whole blood assay
ISSN:1201-9712, 1878-3511, 1878-3511
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:•TB and COVID-19 coinfection does not affect M. tuberculosis-specific response.•TB and COVID-19 coinfection limits the ability to in vitro respond to SARS-CoV-2.•Latent TB infection does not affect the ability to in vitro respond to SARS-CoV-2. The interaction of COVID-19 and tuberculosis (TB) are still poor characterized. Here we evaluated the immune response specific for Micobacterium tuberculosis (Mtb) and SARS-CoV-2 using a whole-blood-based assay-platform in COVID-19 patients either with TB or latent TB infection (LTBI). We evaluated IFN-γ level in plasma from whole-blood stimulated with Mtb antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S). We consecutively enrolled 63 COVID-19, 10 TB-COVID-19 and 11 LTBI-COVID-19 patients. IFN-γ response to Mtb-antigens was significantly associated to TB status and therefore it was higher in TB-COVID-19 and LTBI-COVID-19 patients compared to COVID-19 patients (p ≤ 0.0007). Positive responses against CD4-S were found in 35/63 COVID-19 patients, 7/11 LTBI-COVID-19 and only 2/10 TB-COVID-19 patients. Interestingly, the responders in the TB-COVID-19 group were less compared to COVID-19 and LTBI-COVID-19 groups (p = 0.037 and 0.044, respectively). Moreover, TB-COVID-19 patients showed the lowest quantitative IFN-γ response to CD4-S compared to COVID-19-patients (p = 0.0336) and LTBI-COVID-19 patients (p = 0.0178). Our data demonstrate that COVID-19 patients either TB or LTBI have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to Mtb-specific antigens.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1201-9712
1878-3511
1878-3511
DOI:10.1016/j.ijid.2021.02.090